For example, tumours harbouring NTRK fusions now have targeted options such as Larotrectinib and Entrectinib, while tumours with FGFR2 fusions can be treated with Pemigatinib and Futibatinib, and tumours carrying IDH1 mutations can be treated with Ivosidenib [35,36,37]. This evidence concerns the gene IDH1 and neoplasm.